**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 41709

**Manuscript Type:** MINIREVIEWS

**Instantaneous wave-free ratio (iFR®) to determine hemodynamically significant coronary stenosis: A comprehensive review**

Baumann S *et al.* iFR® to determine coronary stenosis significance

Stefan Baumann, Leonard Chandra, Elizaveta Skarga, Matthias Renker, Martin Borggrefe, Ibrahim Akin, Dirk Lossnitzer

**Stefan Baumann, Leonard Chandra, Elizaveta Skarga, Martin Borggrefe, Ibrahim Akin, Dirk Lossnitzer,** First Department of Medicine-Cardiology, University Medical Center Mannheim, Mannheim, Germany and DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Mannheim 68167, Baden-Württemberg, Germany

**Matthias Renker,** Department of Cardiology, Kerckhoff-Klinik GmbH, Bad Nauheim 61231, Hesse, Germany

**ORCID number:** Stefan Baumann ([0000-0002-9183-7708](http://orcid.org/0000-0002-9183-7708)); Leonard Chandra ([0000-0002-6168-101X](http://orcid.org/0000-0002-6168-101X)); Elizaveta Skarga (0000-0002-6184-9548); Matthias Renker (0000-0002-4756-5397); Martin Borggrefe (0000-0002-3206-934X); Ibrahim Akin (0000-0003-1974-6147); Dirk Lossnitzer (0000-0001-6468-3910).

**Author contributions:** All authors equally contributed to this paper with conception of the literature review, drafting, critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** Dr. Baumann is a consultant for Volcano Corporation Koninklijke Philips N.V. (Amsterdam, Netherlands). All other authors declare that they have no financial disclosure.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author to: Stefan Baumann, MD, Doctor,** First Department of Medicine-Cardiology, University Medical Center Mannheim, Mannheim, Germany and DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Baden-Württemberg, Germany. stefan.baumann@umm.de

**Telephone:** +49-621-3834701

**Fax:** +49-621-3832025

**Received:** August 25, 2018

**Peer-review started:** August 25, 2018

**First decision:** October 5, 2018

**Revised:** October 23, 2018

**Accepted:** November 26, 2018

**Article in press:**

**Published online:**

**Abstract**

Coronary angiography is considered to be the gold standard in the morphological evaluation of coronary artery stenosis. The morphological assessment of the severity of a coronary lesion is very subjective. Thus, the invasive fractional flow reserve (FFR) measurement represents the current standard for estimation of the hemodynamic significance of coronary artery stenosis. The FFR-guided revascularization strategy has been initially classified as a Class-IA-recommendation in the 2014 ESC/EACTS guidelines on myocardial revascularization. Both the DEFER and the FAME studies showed no treatment advantage for hemodynamically insignificant stenoses. With the help of FFR (and targeted interventions), clinical results could be improved; however, the use in clinical practice is still limited due to the need of Adenosine administration and a significant prolongation of the length of the procedure. Instantaneous wave-free ratio (iFR®) is a new innovative approach for the determination of the hemodynamic significance of coronary stenosis, which can be obtained at rest without the use of vasodilators. Regarding the periprocedural complications as well as prognosis, iFR® showed non-inferiority to FFR in the SWEDEHEART and DEFINE-FLAIR trials. Furthermore, iFR®, enhanced by iFR®-pullback, provides the possibility to display the iFR®-change over the course of the vessel to create a hemodynamic map.

**Key words:** Coronary stenosis; Coronary angiography; Fractional flow reserve; Instantaneous wave-free ratio; Myocardial ischemia; Coronary revascularization

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Invasive fractional flow reserve (FFR) measurement represents the current standard for estimation of the hemodynamic significance of coronary artery stenosis and has been initially classified as a Class-IA-recommendation in the 2014 ESC/EACTS guidelines on myocardial revascularization. Instantaneous wave-free ratio (iFR®) is a new innovative approach for the functional evaluation of a coronary stenosis, which can be obtained at rest without the use of vasodilators. The diagnostic value of iFR® showed non-inferiority compared to FFR. It can be enhanced by iFR®-pullback, which provides the possibility to display the iFR®-change over the course of the vessel to create a hemodynamic map.

Baumann S, Chandra L, Skarga E, Renker M, Borggrefe M, Akin I, Lossnitzer D. Instantaneous wave-free ratio (iFR®) to determine hemodynamically significant coronary stenosis: A comprehensive review. *World J Cardiol* 2018; In press

**INTRODUCTION**

The optimal strategy for revascularization of hemodynamically significant coronary stenosis is an important therapeutic option in patients with coronary heart disease (CHD)[1]. Despite being the gold standard in the diagnosis of coronary stenosis, coronary angiography underlies a few limitations. Sometimes, the angiographic demonstration of the correct anatomy is limited due to morphologic deviations; additionally it was established that the visual evaluation of the coronary lesion has a subjective nature and contains a large inter-observer variability[2,3].

The current standard for invasive assessment of a coronary lesion with hemodynamic significance is the fractional flow reserve-(FFR)-measurement[4]. This was initially adopted as a Class-IA-recommendation in the ECS/EACTS guidelines of 2014 on myocardial revascularization[5]. Especially with intermediate coronary stenoses and in patients with a multivessel disease, FFR can help the clinician assess the severity of the lesion and to formulate the required treatment[5]. Other than the angiographic imaging, FFR provides a direct functional assessment of coronary stenoses.

Both the DEFER (Deferral *vs* Performance of Percutaneous Coronary Intervention of Functionally Non-Significant Coronary Stenosis) and the FAME (Flow Reserve *vs* Angiography for multivessel Evaluation) studies could not prove a prognostic benefit of treating hemodynamically insignificant coronary stenosis through percutaneous coronary intervention (PCI)[6-8]. Furthermore, long-term analysis of the DEFER-studies shows, that the use of FFR improved the clinical outcome and lowered the procedural costs[9].

Patients with stable CHD, who received FFR-guided PCI along with an adequate medication appeared to be more convalescent compared to the patients on the medication-only therapy and were subjected to an emergency revascularization less frequently (FAME-II-study[8]). Additionally, patients with hemodynamically insignificant coronary stenoses (FFR > 0.80), who received optimal medical treatment alone, showed a very good long-term outcome.

The FFR utilizes the linear relationship between pressure and flow at a point of an increased intracoronary resistance[10]. Assuming intracoronary pressure is proportional to the flow, a pressure gradient could indicate a lowered blood flow, caused by a coronary stenosis. However, the intracoronary resistance changes periodically during a cardiac cycle. To perform the FFR-measurement Adenosine is administered to the patient to induce a hyperemic condition in order to achieve a constant blood flow. The periodical variations in resistance emerge from the interaction between the myocardium and the microvasculature during systole (high intracoronary resistance, compression of the microvasculature) and diastole (low intracoronary resistance, decompression of the microvasculature[11]). Based on this physiological knowledge during the induced state of hyperemia FFR can be calculated and averaged over several cardiac cycles.

Although the clinical and economical benefit of FFR have been proven[7,9], it is only used in about 6% of patients undergoing PCI for intermediate coronary stenoses (40%-70% diameter stenosis)[12]. This is due to a high price for a single FFR-wire (600-800€[13]), as well as the use of Adenosine, which comes at an additional expense. Furthermore, with each coronary assessment there exists a certain risk of a perforation or dissection[14] whilst applying the wire, coupled with a longer assessment time and the fact that the administration of Adenosine could lead to adverse effects like dyspnea, chest pressure and discomfort, hypotension or even atrioventricular blocks. However vasodilators offer a pragmatic solution to achieving a constant blood flow and stable perfusion. Although FFR delivers accurate results and provides valuable information for the clinician assessing a single stenosis, the process of estimating the severity of each single stenosis in vessels with multiple lesions is difficult and time consuming[15]. Thereby the hemodynamic effect of removing a single stenosis in complex CHD is not easily predictable. The reason for this is an interdependence between multiple lesions in continuous coronary arteries under hyperemia, leading to the examiner overestimating a distal lesion and underestimating a proximal lesion. Inconveniently, after the treatment of each stenosis the segment has to be reassessed by the clinician[16,17]. Therefore, new methods like iFR® (“instantaneous wave-free ratio”, Volcano Corporation, Koninklijke Philips N.V., Amsterdam, The Netherlands) offer a different approach. iFR® is based on the hypothesis that a specific time interval during the cardiac cycle, the diastolic “wave-free” period, can be identified, when microvascular resistance is naturally minimized without the need of hyperemia induced by the administration of a vasodilator[18]. Next to the two large multicenter studies DEFINE-FLAIR[19] and SWEDEHEART[20], which proved the non-inferiority of iFR® towards FFR, the first meta-analysis with 23 studies including 6300 coronary lesions was just recently published. This study verified a significant correlation between iFR® and the gold standard FFR and a good performance of iFR® identifying FFR-positive stenoses[21]. Besides FFR, iFR® was just recently adopted as a Class-IA-recommendation in the ECS/EACTS guidelines of 2018 on myocardial revascularization[22].

**PHYSIOLOGICAL PRINCIPLES OF iFR®-ASSESSMENT**

iFR®-measurement is based on the physical law outlined by the Hagen-Poiseuille equation, which describes a laminar flow of an incompressible viscous fluid flowing through a cylindrical pipe of a constant cross section, which depends on the type of fluid and the consistency of the pipe[23]. This law is a deviation of Ohm’s Law (U = RxI).



At a constant resistance, pressure changes are proportional to change of flow. Whilst, by administering of a vasodilator, the FFR-measurement utilizes this constant resistance proportionality, the iFR®-index is obtained during a period of the cardiac cycle (diastole) when the resistance is minimal and naturally stable. The unique qualities of coronary blood flow result from the proximal pressure changes through pulsatile blood ejection as well as peripheral variations in coronary microcirculation[11]. It is not adequate to assess a stenosis severity by simply measuring the drop in maximum or intermediate pressure of the vessel since the distal predominant pressure is affected by several components and does not necessarily reflect the proximal aortic pressure. The distal predominant pressure is primarily influenced by the pressure changes in the coronary microcirculation, but can significantly affect the (instantaneous) proportion of pressure and blood flow as an index of intracoronary resistance. Wave intensity analysis helps to differentiate between distal and proximal variations[11].

In early systole pressure rises rapidly without an increase in flow velocity (Figure 1). Accordingly, the index of intracoronary resistance rises as well. The rapid increase in pressure (without the flow acceleration) develops from adaption of the ejection wave within the aorta and the compression wave from the coronary microcirculation.

Quite the opposite happens in early diastole: Pressure decreases while flow accelerates, which leads to a rapidly decreasing intracoronary resistance and absorption of blood into the coronary microcirculation. After this short period of pressure decrease the index of coronary resistance is almost minimal and stable, since neither from the proximal nor from the distal coronary end wave activity is emitted. This wave-free period prevails over most of the diastole and is the basis for iFR®-measurement.

**FURTHER IMPROVEMENTS**

Pressure-derived flow indices like FFR refer to a proportional correlation between pressure and flow when resistance is constant[24], which only applies to a specific period of the cardiac cycle. Manipulations with vasodilators primarily reduce the systolic component of the resistance and can thus be used to achieve a minimal and stabile value.

Among the advantages of iFR® are a drug-free approach, as well as the ability of reaching a higher flow velocity during the measurement, which allows a better discrimination of hemodynamically significant stenoses. A series of measured and reproducible data is generated during a period of 5 consecutive heartbeats. Indices of 0.89 or less, generated by iFR®, are equivalent to the common limit of 0.80 or less in FFR[4] and serve as an indicator for ischemia (Figure 2). A clinical example is presented in Figure 3.

To detect the specific time during diastole for the calculation of iFR®, it is necessary to acquire electrocardiographic signals of the patient. To simplify the assessment process it has recently become possible to calculate the index by only using the pressure signals, thus allowing the process to be run ECG independent. Specific end-systolic and end-diastolic waveform characteristics are identified to receive the accurate proximal (Pa) and distal (Pd) coronary pressure[25].

Regarding the assessment of vessels with multiple lesions iFR®-pullback offers a technique to create a hemodynamic map of a coronary artery, which allows an individual estimation of each stenosis. The pullback itself is conducted manually and detects continuously pressure changes per millimeter for a given length[16,17]. Since the iFR® is obtained under resting conditions, whereby the autoregulatory mechanisms in the vessel ensure a stable and constant baseline-flow, serial lesions are not affected by each other[26].

Baseline physiology offers the opportunity to quantify the impact of each single stenosis and can therefore predict the effect of a treatment of an individual stenosis within a vessel with multiple lesions. A hemodynamic map via pullback can simultaneously display iFR®-changes over the whole vessel and track down the lesion with the predominant pressure-loss[16]. Additionally, it can be overlayed with angiographic imaging in order to locate the exact physiologically significant anatomical site of the narrowings (co-registration)[17].

Other diastolic resting indices like the diastolic pressure ratio (dPR) obtained in different phases of the diastole like dPR*25–75* (25% to 75% of diastole) or dPR*mid*(midpoint of diastole) along withMatlab calculated iFR® (iFR*matlab*) and iFR®-like indexes shortening the length of the wave-free period by 50 and 100 ms (iFR-50ms and iFR-100ms) were compared to the iFR® and found to be numerically identical. Therefore, all guidelines and cut-off values as well as clinical recommendation can be applied to these indices[27].

**CLINICAL STUDIES ABOUT THE ~~-~~ iFR®-MEASUREMENT**

During the course of the initial pilot study Adenosine Vasodilator Independent Stenosis Evaluation (ADVISE) a wave-free period during the cardiac cycle was identified for the first time, enabling to determine stenosis severity without the administration of vasodilators. It was an international, multicenter, non-randomized study (Table 1), in which the flow and pressure data from 157 stenoses was collected. The study revealed a good correlation between the FFR- and iFR®-measurements. However, with only 131 patients the population was relatively small. In this population the iFR®-index 0.83 showed the best correlation with the FFR-index of 0.80. A subgroup analysis in patients with multivessel disease, similar to the FAME-study collective, confirmed an excellent diagnostic correlation of 93% between iFR® and FFR.

The RESOLVE (Multicenter Core Laboratory Comparison if Instantaneous Wave-Free Ratio and Resting Pd/Pa with Fractional Flow Reserve)-study tried to examine the diagnostic accuracy of iFR® versus FFR. In the course of this retrospective, multicenter, non-randomized study, 1593 (81%) out of 1974 lesions were analyzed, as 381 lesions had to be excluded due to the inadequate image quality. Despite this the result showed a moderate correlation between iFR® and FFR with a diagnostic precision of 80.4%.

DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization) - a leading multicenter, international, randomized, blinded study, designed to prove the non-inferiority of iFR®, reiterated the findings of the previously mentioned studies. As of now, the available data is based on a one-year-analysis. The ongoing study is conducted in 49 places in over 19 countries. Patients were included if they had at least one angiographically confirmed coronary disease, in which there was at least one stenosis of a questionable hemodynamic severity. Suitable patients were randomly assigned to a particular arm at a ratio of 1:1 FFR towards iFR®. The primary endpoint was the one-year risk for major adverse cardiac events like CV death, nonfatal myocardial infarction or unplanned revascularization. From January 2014 to December 2015, 2492 patients were included, 1242 in the iFR®- and 1250 in the FFR-group. The one-year analysis showed comparable results regarding the endpoints, confirming the non-inferiority of iFR® towards FFR. The length of the procedure time was significantly shorter in the iFR®-group (iFR® 40.5 min, FFR: 45.0 min; *P* < 0.001) and less patients suffered from adverse effects like angina pectoris and dyspnea (3.1% *vs* 30.8%, *P* < 0.001), mainly because of the absent administration of Adenosine. What is more, in comparison to FFR, this method was identified as a more economically advantageous.

Published at about the same time, iFR®-SWEDEHEART (Instantaneous Wave-Free Ratio versus Fractional Flow Reserve to Guide PCI) also examined the non-inferiority of iFR® in the course of a multicenter, randomized, clinical study. The inclusion of eligible patients was based on the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2037 patients with a stable angina pectoris or an acute coronary syndrome (ACS) were included and randomly allocated in the particular arm (iFR® *vs* FFR). Primary endpoint was the one-year risk for major adverse cardiac effects like cardiovascular death, nonfatal myocardial infarction or unplanned revascularization. Information about myocardial infarction or unplanned revascularization was gathered from the web-based register SWEDEHEART (Swedish Web-Based System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). The study was conducted in 15 places (13 in Sweden, 1 in Denmark, 1 in Iceland). The patients were recruited from May 2014 to October 2015. Of these 2037 patients, 1019 received iFR® and 1018 - FFR. Final analysis included 2019 patients, due to the fact that 18 participants had to be excluded because of the adverse effects under Adenosine or technical problems.

The one-year analysis of endpoints confirmed the non-inferiority of the iFR®-method. Especially in uncertain cases, where iFR® and FFR results differ, the data indicates that iFR® provides more accurate results. FFR-measurement tends to overrate the severity, since the vasodilator dependent hyperemia leads to a pressure decrease. The number of hemodynamically significant stenoses in this trial was much lower than in the FAME-study population, which only included patients with multivessel diseases. The iFR®-SWEDEHEART population is a better representation of the reality in clinical practice, since every patient with the indication for invasive coronary assessment could be included, independent of his coronary status. Additionally, as described by Tonino and de Bruyne[7], an improvement in the clinical outcome of FFR-guided PCI was shown.

To compare ECG-independent iFR® calculation and the current method using ECG and pressure signals. Petraco *et al*[25] tested the only pressure-dependent iFR® algorithm in 320 coronary hemodynamically significant stenoses which were already included in multicenter studies (ADVISE[18], ADVISE Registry study[28] and a study by Nijjer *et al*[17]). The iFR®-indices of both methods correlated highly (r = 0.9997) which makes the ECG-independent iFR® applicable to the recent results of DEFINE-FLAIR and SWEDEHEART[25].

Based on the RESOLVE and ADVISE, Nijjer *et al*[17] have conducted a study (Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Provides Virtual Intervention and Predicts Hemodynamic Outcome for Serial Lesions and Diffuse Coronary Artery Disease) to create a hemodynamic map using the motorized pullback with iFR®, questioning if it helps to predict the stent impact in tandem and diffusely diseased vessels[17]. Thirty-two coronary arteries with 2 or more stenoses in 29 patients were assessed and went through PCI. After physiological mapping, a computer-aided simulation calculated the best-case PCI effect. First, the virtual and real-world stents were compared to examine the predictive capability of iFR®-pullback. Second, the length of virtual stents, only positioned in areas with a high iFR®-intensity loss, was compared to the length of real world stents. **Δ**iFR®(exp) and **Δ**iFR®(obs) showed a strong relationship (r = 0.97, *P* < 0.001) and post-PCI iFR® was predicted with a 2% ± 1% error. Furthermore, the hereby examined physiological lesion length was significantly shorter than the anatomical length obtained by QCA (12.6 ± 1.5 mm *vs* 23.3 ± 1.3 mm, *P* < 0.001) and the length of the stent that was implanted in reality (27.5 ± 2.3 mm, *P* < 0.001).

Another study, published in 2017, realized by Kawase *et al*[29] (Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results) wanted to evaluate the accuracy of the predicted iFR®-value compared to the iFR® result, that was observed in reality after PCI. Additionally, they tried to discover potential factors for a failed prediction. iFR® ratios of 73 lesions in 71 patients were compared retrospectively before and after the coronary intervention. Pullback was conducted manually, anatomic lesion length was obtained by QCA and the cut-off value of a difference between iFR®(pre) and iFR®(obs) was set at 0.036. The cut-off point was slightly missed with a calculated mean difference of 0.036 ± 0.037 although values correlated adequately (r = 0.756). In the course of a multivariate regression analysis only a residual pressure gradient remained as an independent risk factor, leading to a failed prediction. After Subtraction of the residual pressure gradient the correlation between iFR®(pre) and iFR®(obs) improved. The only risk factors for a residual pressure gradient appeared to be a small diameter of the implanted stent and a high APPROACH-score[30] - a score that calculates the amount of blood supplied to the myocardium by the targeted vessel. Kawase *et al*[29] noted that a larger cohort study could identify additional factors that have caused a failed prediction. An overview about the most important current publications is composed in Table 1. Our manuscript is based on the review of previous published articles and did not involve animal or human subjects. Therefore, neither an ethical approval nor a patient consent was necessary.

**LIMITATIONS**

The process of advancing the coronary-pressure guide wire in FFR-measurement is still occasionally criticized and potentially accompanied by complications, which similarly constitutes a limitation of iFR®-measurement. This could hinder the regular clinical use of FFR- or iFR®-measurement.

It is not completely clarified~~,~~ how to proceed in uncertain cases and whether a stress test with Adenosine is to be indicated. If hyperemia cannot be achieved through adequate doses, it is possible that the calculated value does not reflect the real FFR[31]. First, Adenosine leads to peripheral vasoconstriction transmitted by pulmonary receptors, followed by its immediate effect on larger arteries that leads to a drop in blood pressure. This circumstance makes the ratio dependent on the time of measurement[32]. There is a small number of cases, where not truly flow-limiting stenoses have led to acceptable iFR®-gradients, but at the same time false positive hyperemic pressure gradients (FFR)[31]. High incidents of patient related discomfort, like dyspnea, chest pain, hypotension and AV-blocks or in one recorded case even ventricular fibrillation[33] still remain a limitation of the application of Adenosine[34] which can be overcome by an Adenosine free assessment like the iFR®.

In the analysis about the accuracy of the prediction of post-PCI iFR®, Kawase identified the residual pressure gradient as a risk factor for ~~a~~ the failed prediction and mentioned that its consideration might help the examining clinician[29].

Regarding microvascular diseases, studies could not prove a correlation between FFR and the index of microvasculatory resistance, an index for the microvascular status, measured by the thermodilution technique[35]. This must not be seen as a shortcoming of the FFR method since it might rather show that micro- and macrovascular diseases are caused by different disease processes[36]. These findings can be employed on iFR®, since its non-inferiority towards FFR was proven.

Finally, there are currently new studies expected, in which the iFR®-technique is to be subjected to the specific questioning, i.e. the sequential assessment of stenosis. A reduction in costs is to be expected due to the absent administration of Adenosine and shortened procedural time.

**CONCLUSION**

The current standard of cardiac invasive ischemic diagnostic is invasive FFR-measurement, which was initially adopted as a Class-IA-recommendation to the ECS/EACTS guidelines of 2014 on myocardial revascularization. Despite the good existing evidence, the performance of pressure-derived functional assessment in daily routine is still limited. Here iFR® provides a new innovative approach to assess coronary stenosis severity without administering vasodilators. Besides FFR, iFR® was just recently adopted as a Class-IA-recommendation in the ECS/EACTS guidelines of 2018 on myocardial revascularization[22]. Additionally, the eliminated necessity to record the electrocardiographic signals simplifies the procedure of the invasive functional assessment.

iFR®, extended by iFR®-pullback, can help achieve a better physiological result in treating vessels with multiple lesions by creating a hemodynamic map. Since implanting potentially larger stents to prevent a geographical miss is currently the standard in treating multivessel disease, a physiologically justified stent length might therefore be more hemodynamically beneficial for the vessel[16]. Thereby factors, like a residual pressure gradient and other potential not yet discovered influences that have led to an inaccurate prediction of post-PCI iFR® ratio have to be considered. Large-scale multicenter, randomized studies demonstrated the non-inferiority of iFR® to FFR, whilst requiring less procedural time, lower costs and having a lower number of the patients suffering from adverse effects due to a spared use of Adenosine.

**ACKNOWLEDGEMENTS**

We would like to thank Volcano Corporation, Koninklijke Philips N.V. (Amsterdam,

The Netherlands) for providing the image copyrights of Figure 1.

**REFERENCES**

1 **Nef H**, Renker M, Hamm CW; European Society of Cardiology; European Association for Cardio-thoracic Surgery. [ESC/EACTS guidelines on myocardial revascularization: Amendments 2014]. *Herz* 2014; **39**: 913-918 [PMID: 25406330 DOI: 10.1007/s00059-014-4180-4]

2 **Zir LM**, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. *Circulation* 1976; **53**: 627-632 [PMID: 1253383 DOI: 10.1161/01.CIR.53.4.627]

3 **Kleiman NS**, Rodriguez AR, Raizner AE. Interobserver variability in grading of coronary arterial narrowings using the American College of Cardiology/American Heart Association grading criteria. *Am J Cardiol* 1992; **69**: 413-415 [PMID: 1734658 DOI: 10.1016/0002-9149(92)90245-T]

4 **Pijls NH**, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med* 1996; **334**: 1703-1708 [PMID: 8637515 DOI: 10.1056/NEJM199606273342604]

5 **Authors/Task Force members**, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014; **35**: 2541-2619 [PMID: 25173339 DOI: 10.1093/eurheartj/ehu278]

6 **Pijls NH**, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bär F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol* 2007; **49**: 2105-2111 [PMID: 17531660 DOI: 10.1016/j.jacc.2007.01.087]

7 **Tonino PA**, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 2009; **360**: 213-224 [PMID: 19144937 DOI: 10.1056/NEJMoa0807611]

8 **De Bruyne B**, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012; **367**: 991-1001 [PMID: 22924638 DOI: 10.1056/NEJMoa1205361]

9 **Fearon WF**, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U; Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. *Circulation* 2010; **122**: 2545-2550 [PMID: 21126973 DOI: 10.1161/CIRCULATIONAHA.109.925396]

10 **Spaan JA**, Piek JJ, Hoffman JI, Siebes M. Physiological basis of clinically used coronary hemodynamic indices. *Circulation* 2006; **113**: 446-455 [PMID: 16432075 DOI: 10.1161/CIRCULATIONAHA.105.587196]

11 **Davies JE**, Whinnett ZI, Francis DP, Manisty CH, Aguado-Sierra J, Willson K, Foale RA, Malik IS, Hughes AD, Parker KH, Mayet J. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. *Circulation* 2006; **113**: 1768-1778 [PMID: 16585389 DOI: 10.1161/CIRCULATIONAHA.105.603050]

12 **Kleiman NS**. Bringing it all together: integration of physiology with anatomy during cardiac catheterization. *J Am Coll Cardiol* 2011; **58**: 1219-1221 [PMID: 21903053 DOI: 10.1016/j.jacc.2011.06.019]

13 **Dale M**. The Pressure Wire fractional flow reserve measurement system for coronary artery disease. Briefing, 2014. Available from: URL: https://www.nice.org.uk/advice/mib2/resources/the-pressurewire-fractional-flow-reserve-measurement-system-for-coronary-artery-disease-1763862133957

14 **Tavakol M**, Ashraf S, Brener SJ. Risks and complications of coronary angiography: a comprehensive review. *Glob J Health Sci* 2012; **4**: 65-93 [PMID: 22980117 DOI: 10.5539/gjhs.v4n1p65]

15 **Kim HL**, Koo BK, Nam CW, Doh JH, Kim JH, Yang HM, Park KW, Lee HY, Kang HJ, Cho YS, Youn TJ, Kim SH, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB. Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery. *JACC Cardiovasc Interv* 2012; **5**: 1013-1018 [PMID: 23078728 DOI: 10.1016/j.jcin.2012.06.017]

16 **Nijjer SS**, Sen S, Petraco R, Mayet J, Francis DP, Davies JE. The Instantaneous wave-Free Ratio (iFR) pullback: a novel innovation using baseline physiology to optimise coronary angioplasty in tandem lesions. *Cardiovasc Revasc Med* 2015; **16**: 167-171 [PMID: 25977227 DOI: 10.1016/j.carrev.2015.01.006]

17 **Nijjer SS**, Sen S, Petraco R, Escaned J, Echavarria-Pinto M, Broyd C, Al-Lamee R, Foin N, Foale RA, Malik IS, Mikhail GW, Sethi AS, Al-Bustami M, Kaprielian RR, Khan MA, Baker CS, Bellamy MF, Hughes AD, Mayet J, Francis DP, Di Mario C, Davies JE. Pre-angioplasty instantaneous wave-free ratio pullback provides virtual intervention and predicts hemodynamic outcome for serial lesions and diffuse coronary artery disease. *JACC Cardiovasc Interv* 2014; **7**: 1386-1396 [PMID: 25459526 DOI: 10.1016/j.jcin.2014.06.015]

18 **Sen S**, Escaned J, Malik IS, Mikhail GW, Foale RA, Mila R, Tarkin J, Petraco R, Broyd C, Jabbour R, Sethi A, Baker CS, Bellamy M, Al-Bustami M, Hackett D, Khan M, Lefroy D, Parker KH, Hughes AD, Francis DP, Di Mario C, Mayet J, Davies JE. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. *J Am Coll Cardiol* 2012; **59**: 1392-1402 [PMID: 22154731 DOI: 10.1016/j.jacc.2011.11.003]

19 **Davies JE**, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. *N Engl J Med* 2017; **376**: 1824-1834 [PMID: 28317458 DOI: 10.1056/NEJMoa1700445]

20 **Götberg M**, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Öhagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Tödt T, Venetsanos D, James SK, Kåregren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Fröbert O; iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *N Engl J Med* 2017; **376**: 1813-1823 [PMID: 28317438 DOI: 10.1056/NEJMoa1616540]

21 **De Rosa S**, Polimeni A, Petraco R, Davies JE, Indolfi C. Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Flow Reserve. *Circ Cardiovasc Interv* 2018; **11**: e004613 [PMID: 29326150 DOI: 10.1161/CIRCINTERVENTIONS.116.004613]

22 **Neumann FJ**, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2018 [PMID: 30165437 DOI: 10.1093/eurheartj/ehy394]

23 **Nijjer S**, Davies J. Physiologic assessment in the cardiac catheterization laboratory: CFR, FFR, iFR®, and beyond. In: Dangas GD, Di Mario C, Kipshidze NN. Interventional cardiology: principles and practice, second edition. Wiley Blackwell, 2017: 59-70

24 **Pijls NH**, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. *Circulation* 1993; **87**: 1354-1367 [PMID: 8462157 DOI: 10.1161/01.CIR.87.4.1354]

25 **Petraco R**, Sen S, Nijjer S, Malik IS, Mikhail GW, Al-Lamee R, Cook C, Baker C, Kaprielian R, Foale RA, Mayet J, Francis DP, Davies JE. ECG-Independent Calculation of Instantaneous Wave-Free Ratio. *JACC Cardiovasc Interv* 2015; **8**: 2043-2046 [PMID: 26738677 DOI: 10.1016/j.jcin.2015.10.005]

26 **Uren NG**, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. *N Engl J Med* 1994; **330**: 1782-1788 [PMID: 8190154 DOI: 10.1056/NEJM199406233302503]

27 **Van't Veer M**, Pijls NHJ, Hennigan B, Watkins S, Ali ZA, De Bruyne B, Zimmermann FM, van Nunen LX, Barbato E, Berry C, Oldroyd KG. Comparison of Different Diastolic Resting Indexes to iFR: Are They All Equal? *J Am Coll Cardiol* 2017; **70**: 3088-3096 [PMID: 29268922 DOI: 10.1016/j.jacc.2017.10.066]

28 **Petraco R**, Escaned J, Sen S, Nijjer S, Asrress KN, Echavarria-Pinto M, Lockie T, Khawaja MZ, Cuevas C, Foin N, Broyd C, Foale RA, Hadjiloizou N, Malik IS, Mikhail GW, Sethi A, Kaprielian R, Baker CS, Lefroy D, Bellamy M, Al-Bustami M, Khan MA, Hughes AD, Francis DP, Mayet J, Di Mario C, Redwood S, Davies JE. Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. *EuroIntervention* 2013; **9**: 91-101 [PMID: 22917666 DOI: 10.4244/EIJV9I1A14]

29 **Kawase Y**, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, Hirakawa A, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. *J Cardiol* 2018; **71**: 458-463 [PMID: 29203079 DOI: 10.1016/j.jjcc.2017.10.022]

30 **Graham MM**, Faris PD, Ghali WA, Galbraith PD, Norris CM, Badry JT, Mitchell LB, Curtis MJ, Knudtson ML; APPROACH Investigators (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. *Am Heart J* 2001; **142**: 254-261 [PMID: 11479464 DOI: 10.1067/mhj.2001.116481]

31 **Nijjer SS**, Sen S, Petraco R, Davies JE. Advances in coronary physiology. *Circ J* 2015; **79**: 1172-1184 [PMID: 25865272 DOI: 10.1253/circj.CJ-15-0044]

32 **Tarkin JM**, Nijjer S, Sen S, Petraco R, Echavarria-Pinto M, Asress KN, Lockie T, Khawaja MZ, Mayet J, Hughes AD, Malik IS, Mikhail GW, Baker CS, Foale RA, Redwood S, Francis DP, Escaned J, Davies JE. Hemodynamic response to intravenous adenosine and its effect on fractional flow reserve assessment: results of the Adenosine for the Functional Evaluation of Coronary Stenosis Severity (AFFECTS) study. *Circ Cardiovasc Interv* 2013; **6**: 654-661 [PMID: 24254709 DOI: 10.1161/CIRCINTERVENTIONS.113.000591]

33 **Buccheri D**, Sorce S, Piraino D, Andolina G. Fractional flow reserve: A useful tool for interventionists which should be used with caution! *Int J Cardiol* 2016; **221**: 404-405 [PMID: 27404714 DOI: 10.1016/j.ijcard.2016.06.303]

34 **Götberg M**, Cook CM, Sen S, Nijjer S, Escaned J, Davies JE. The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. *J Am Coll Cardiol* 2017; **70**: 1379-1402 [PMID: 28882237 DOI: 10.1016/j.jacc.2017.07.770]

35 **Lee JM**, Layland J, Jung JH, Lee HJ, Echavarria-Pinto M, Watkins S, Yong AS, Doh JH, Nam CW, Shin ES, Koo BK, Ng MK, Escaned J, Fearon WF, Oldroyd KG. Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: insights from the International Index of Microcirculatory Resistance Registry. *Circ Cardiovasc Interv* 2015; **8**: e002857 [PMID: 26499500 DOI: 10.1161/CIRCINTERVENTIONS.115.002857]

36 **Yong AS**, Ho M, Shah MG, Ng MK, Fearon WF. Coronary microcirculatory resistance is independent of epicardial stenosis. *Circ Cardiovasc Interv* 2012; **5**: 103-108, S1-S2 [PMID: 22298800 DOI: 10.1161/CIRCINTERVENTIONS.111.966556]

37 **Berry C**, van 't Veer M, Witt N, Kala P, Bocek O, Pyxaras SA, McClure JD, Fearon WF, Barbato E, Tonino PA, De Bruyne B, Pijls NH, Oldroyd KG. VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice): a multicenter study in consecutive patients. *J Am Coll Cardiol* 2013; **61**: 1421-1427 [PMID: 23395076 DOI: 10.1016/j.jacc.2012.09.065]

38 **Sen S**, Asrress KN, Nijjer S, Petraco R, Malik IS, Foale RA, Mikhail GW, Foin N, Broyd C, Hadjiloizou N, Sethi A, Al-Bustami M, Hackett D, Khan MA, Khawaja MZ, Baker CS, Bellamy M, Parker KH, Hughes AD, Francis DP, Mayet J, Di Mario C, Escaned J, Redwood S, Davies JE. Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (Classification Accuracy of Pressure-Only Ratios Against Indices Using Flow Study). *J Am Coll Cardiol* 2013; **61**: 1409-1420 [PMID: 23500218 DOI: 10.1016/j.jacc.2013.01.034]

39 **Park JJ**, Petraco R, Nam CW, Doh JH, Davies J, Escaned J, Koo BK. Clinical validation of the resting pressure parameters in the assessment of functionally significant coronary stenosis; results of an independent, blinded comparison with fractional flow reserve. *Int J Cardiol* 2013; **168**: 4070-4075 [PMID: 23890849 DOI: 10.1016/j.ijcard.2013.07.030]

40 **Jeremias A**, Maehara A, Généreux P, Asrress KN, Berry C, De Bruyne B, Davies JE, Escaned J, Fearon WF, Gould KL, Johnson NP, Kirtane AJ, Koo BK, Marques KM, Nijjer S, Oldroyd KG, Petraco R, Piek JJ, Pijls NH, Redwood S, Siebes M, Spaan JAE, van 't Veer M, Mintz GS, Stone GW. Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. *J Am Coll Cardiol* 2014; **63**: 1253-1261 [PMID: 24211503 DOI: 10.1016/j.jacc.2013.09.060]

41 **Petraco R**, Al-Lamee R, Gotberg M, Sharp A, Hellig F, Nijjer SS, Echavarria-Pinto M, van de Hoef TP, Sen S, Tanaka N, Van Belle E, Bojara W, Sakoda K, Mates M, Indolfi C, De Rosa S, Vrints CJ, Haine S, Yokoi H, Ribichini FL, Meuwissen M, Matsuo H, Janssens L, Katsumi U, Di Mario C, Escaned J, Piek J, Davies JE. Real-time use of instantaneous wave-free ratio: results of the ADVISE in-practice: an international, multicenter evaluation of instantaneous wave-free ratio in clinical practice. *Am Heart J* 2014; **168**: 739-748 [PMID: 25440803 DOI: 10.1016/j.ahj.2014.06.022]

42 **Indolfi C**, Mongiardo A, Spaccarotella C, Torella D, Caiazzo G, Polimeni A, Sorrentino S, Micieli M, Sabatino J, Curcio A, De Rosa S. The instantaneous wave-free ratio (iFR) for evaluation of non-culprit lesions in patients with acute coronary syndrome and multivessel disease. *Int J Cardiol* 2015; **178**: 46-54 [PMID: 25464218 DOI: 10.1016/j.ijcard.2014.03.210]

43 **Escaned J**, Echavarría-Pinto M, Garcia-Garcia HM, van de Hoef TP, de Vries T, Kaul P, Raveendran G, Altman JD, Kurz HI, Brechtken J, Tulli M, Von Birgelen C, Schneider JE, Khashaba AA, Jeremias A, Baucum J, Moreno R, Meuwissen M, Mishkel G, van Geuns RJ, Levite H, Lopez-Palop R, Mayhew M, Serruys PW, Samady H, Piek JJ, Lerman A; ADVISE II Study Group. Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance: Results of ADVISE II International, Multicenter Study (ADenosine Vasodilator Independent Stenosis Evaluation II). *JACC Cardiovasc Interv* 2015; **8**: 824-833 [PMID: 25999106 DOI: 10.1016/j.jcin.2015.01.029]

44 **Härle T**, Bojara W, Meyer S, Elsässer A. Comparison of instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR)--first real world experience. *Int J Cardiol* 2015; **199**: 1-7 [PMID: 26179896 DOI: 10.1016/j.ijcard.2015.07.003]

45 **van de Hoef TP**, Petraco R, van Lavieren MA, Nijjer S, Nolte F, Sen S, Echavarria-Pinto M, Henriques JP, Koch KT, Baan J Jr, de Winter RJ, Siebes M, Spaan JA, Tijssen JG, Meuwissen M, Escaned J, Davies JE, Piek JJ. Basal stenosis resistance index derived from simultaneous pressure and flow velocity measurements. *EuroIntervention* 2016; **12**: e199-e207 [PMID: 27290679 DOI: 10.4244/EIJV12I2A33]

**P-Reviewer:** Barik R, Dai X, Lai S, Lin GM, Vermeersch P **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Cardiac and cardiovascular systems

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Proximal pressure and distal pressure during a wave-free period (grey shaded).** Courtesy of Volcano Corporation, Koninklijke Philips N.V. Amsterdam, The Netherlands. Pa: Proximal pressure; Pd: Distal pressure.



**Figure 2 Instantaneous wave-free ratio (iFR®) cut-off value and fractional flow reserve-measurement: An iFR®-value of ≤0.89 indicates a hemodynamically significant stenosis (above, red bars), whereas an iFR®-value of ≥ 0.90 indicates no need for an intervention (green bar).** Accordingly, fractional flow reserve-(FFR)-indices of ≤ 0.80 lead to a revascularization, whereas FFR-indices of > 0.80 indicate a non-significant coronary stenosis. iFR®: Instantaneous wave-free ratio; FFR: Fractional flow reserve.



**Figure 3 Case of a 69-year-old patient with symptoms of angina pectoris and a history of smoking (30 pack-years).** A: Coronary angiography shows an initial two-vessel disease with a significant stenosis of the proximal left anterior descending artery (LAD) before percutaneous coronary intervention; B: Instantaneous wave-free ratio-(iFR®)-measurement was performed in the proximal LAD (iFR® = 0.63; bolt). FFR: Fractional flow reserve.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1 Significant instantaneous wave-free ratio-(iFR®)-studies** | | | | | | | | | | | | |
|  | **Advise** | **Verifiy** | **Clarifiy** | **Park *et al*[39]** | **Resolve** | **Advise in practice** | **Indolfi *et al*[42]** | **ADVISE II** | **Harle *et al*[44]** | **Van de Hoef *et al*[45]** | **DEFINE-FLAIR** | **iFR®-SWEDHEART** |
| First author journal and year of Publication | Sen *et al*[18]. *J* *Am Coll Cardiol* 2012 | Berry *et al*[37]. *J* *Am Coll Cardiol* 2013 | Sen *et al*[38]. *J Am Coll Cardiol* 2013 | Park *et al*[39]. *Int J Cardiol* 2013 | Jeremias *et al*[40]. *J Am Coll Cardiol* 2014 | Petraco *et al*[41]. *Am Heart J* 2014 | Indolfi *et al*[42]. *Int J Cardiol* 2015 | Escaned *et al*[43]*. J Am Coll Cardiol-Intv* 2015 | Harle *et al*[44]*. Int J Cardiol* 2015 | Van de Hoef *et al*[45]*. Euro-Intervention* 2015 | Davies *et al*[19]*. N Engl J Med* 2017 | Götberg *et al*[20]. *N Engl J Med* 2017 |
| Study design | PC, multicenter, non-randomized | PC, multicenter, non-randomized | PC, multicenter | PC, multicenter, non-randomized | RS, multicenter, non-randomized | PC, multicenter, non-randomized | PC, monocenter, non-randomized | PC, multicenter, non-randomized | PC, monocenter, non-randomized | PC, multicenter, non-randomized | PC, multicenter, randomized | PC, multicenter, randomized |
| Countries (centers) | 2 (3) | 6 (6) | 2 (3) | 1 (2) | 7 (15) | 101 (16) | 1 (1) | 8 (45) | 1 (1) | 3 (7) | 19 (49) | 3 (14) |
| Included patients | 131 | 206 | 51 | 238 | 1768 | 313 | 82 | 598 | 109 | 228 (iFR® = 66) | 2492 (iFR® = 1242) | 2037 (iFR® = 1019 |
| Stenoses | 157 | 206 | 51 | 238 | 1974 | 392 | 123 | 690 | 151 | 299 (iFR® = 85) | 3183 (iFR® = 1575) | 3004 (iFR® = 1568) |
| Hemodynamic relevant stenoses (%) | N/A | 134 (65) | N/A | 103 (43.3) | N/A | 153 (39) | 37 (30.1) | 248 (35.9) | N/A | N/A | 451 (28.6) | 457 (29.1) |
| Age in years ± SD | 62.6 ± 10.2 | 65.2 ± 10.2 | 66.2 ± 9.2 | 62.8 ± 0.6 | 63.4 ± 10.3 | 67 ± 11 | 64 ± 9 | 63.6 ± 10.8 | 67 ± 11 | 58 ± 11 | 65.5 ± 10.8 | 67.6 ± 9.6 |
| Men (%) | 83.5 | 71 | 82.4 | 68 | 74.9 | 79 | 81.7 | 68.9 | 63.9 | 68 | 77.5 | 74.2 |
| Diabetes mellitus (%) | 54 (34.4) | 50 (24) | 14 (27.4) | 66 (28) | 497 (28.1) | 94 (30) | 14 (17.1) | 209 (35) | N/A | 10 (15) | 382 (30.8) | 232 (22.8) |
| Hypertonia (%) | 88 (56.1) | 137 (67) | 18 (35.2) | 133 (56) | N/A | 232 (74) | 61 (74.4) | 471 (78.8) | N/A | 25 (38) | 873 (70.3) | 730 (71.6) |
| Smoking (%) | 34 (21.7) | 64 (31) | 15 (29.4) | 64 (27) | 520 (29.4) | 160 (51) | 49 (59.8) | 135 (22.6) | N/A | 21 (32) | 243 (19.6) | 159 (15.6) |
| One-vessel CAD (%) | 108 (68.8) | 85 (41) | N/A | N/A | N/A | 113 (36) | 50 (61) | N/A | 75 (69.4) | N/A | N/A | 452 (44.3) |
| Multi-vessel CAD (%) | 49 (31.2) | 105 (51) | N/A | N/A | 951 (53.8) | 197 (63) | 32 (39) | N/A | 33 (30.6) | N/A | 505 (40.7) | 364 (35.7) |
| Stable angina (%) | 151 (96.2) | 140 (68) | N/A | 151 (63) | 1216 (68.6) | 228 (73) | 29 (35) | 320 (53.5) | N/A | N/A | 986 (79.4) | 632 (62.0) |
| Unstable angina (%) | 6 (3.8) | 46 (22) | N/A | 84 (36) | 255 (14.4) | 85 (27) | 53 (65) | 151 (25.3) | N/A | N/A | 186 (15.0) | 211 (20.7) |
| iFR® cut-off | 0.83 | ≤ 0.83 | 0.86 | 0.90 | 0.90 | 0.90 | 0.92 | 0.89 | 0.896 | 0.90 | 0.89 | 0.89 |
| MACE-rate after 1 yr (iFR® *vs* FFR, *P*-value) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.8 *vs* 7.0 (*P* = 0.003) | 6.7 *vs* 6.1 (*P* = 0.007) |
| Adverse events (iFR® *vs* FFR, *P*-value) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.1 *vs* 30.8 (*P* < 0.001) | 3.0 *vs* 68.3 (*P* < 0.0001) |
| Diagnostic accurracy in % (iFR® *vs* FFR) | 93 | 68 | 92.3 | 82 | 80.4 | 80 | 81.3 | 82.5 | 83.4 | N/A | N/A | N/A |

PC: Prospective cohort study; RS: Retrospective study; FFR: Fractional flow reserve; N/A: Not available; MACE: Major adverse cardiac events.